Prodrug for tumor therapy

Scientists of the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-Molar range) as well as a selective tumor therapy through their prodrugs based on the Antibody Directed Enzyme Prodrug Therapy (ADEPT). Selective is achieved by the specific tumor targeting through the antibody. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site through the enzyme, which is coupled to the antibody. While prodrugs have a low cytotoxicity, active drugs show an unbelievable cytotoxicity in the pico-molar range, much higher than actually used Doxorubicin. The drugs could be used equivalent to current chemotherapeutic agents or combined with e.g. a targeting-antibody.

We are now looking for companies, which are interested in licensing, developing and commercializing our approach.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-152

Contact
Dr. Jens-Peter Horst